Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Upstream Bio, Inc. (NASDAQ:UPB) have been given an average rating of “Moderate Buy” by the five analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $45.25.

A number of brokerages have recently issued reports on UPB. Evercore began coverage on Upstream Bio in a research report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 target price on the stock. Lifesci Capital initiated coverage on shares of Upstream Bio in a report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. Finally, Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th.

Upstream Bio Trading Up 0.3%

Shares of UPB stock opened at $7.70 on Tuesday. Upstream Bio has a 12-month low of $5.14 and a 12-month high of $33.68. The business’s 50 day moving average is $23.72 and its two-hundred day moving average is $22.65. The company has a market capitalization of $416.11 million, a P/E ratio of -4.10 and a beta of 3.00.

Hedge Funds Weigh In On Upstream Bio

Several hedge funds and other institutional investors have recently made changes to their positions in UPB. Bain Capital Life Sciences Investors LLC grew its holdings in Upstream Bio by 6.3% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company’s stock valued at $26,786,000 after buying an additional 144,216 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Upstream Bio by 57.5% during the 2nd quarter. Geode Capital Management LLC now owns 646,635 shares of the company’s stock worth $7,101,000 after acquiring an additional 235,958 shares during the period. Norges Bank acquired a new position in shares of Upstream Bio during the 2nd quarter valued at about $10,650,000. Virtus Investment Advisers LLC purchased a new stake in shares of Upstream Bio in the second quarter valued at about $89,000. Finally, Police & Firemen s Retirement System of New Jersey increased its position in Upstream Bio by 133.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 7,833 shares of the company’s stock worth $86,000 after purchasing an additional 4,483 shares during the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.